Johnson & Johnson highlights long-term pipeline, shares backed by defensive healthcare profile

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-28, 13:26.

Johnson & Johnson (US4781601046) continues to position its business for long-term growth in pharmaceuticals and medtech. Recent investor materials highlight a broad late-stage pipeline, with the stock seen as a defensive healthcare holding alongside peers such as Pfizer and Abbott Laboratories.Johnson & Johnson investor presentation

Pipeline and portfolio focus

In its latest corporate presentation, Johnson & Johnson outlines more than 20 pivotal trials expected to read out over the next several years, spanning immunology, oncology and cardiovascular indications.Johnson & Johnson investor relations overview The company reiterates a long-term pharmaceutical sales growth ambition in the mid-single to high-single-digit percentage range, supported by products such as Darzalex in multiple myeloma and Stelara in immune-mediated diseases.Reuters coverage of J&J pharma pipeline strategy

Medtech remains the second pillar, with Johnson & Johnson highlighting opportunities in electrophysiology, robotic surgery and orthopedic reconstruction.Johnson & Johnson medtech business update Management points to aging populations and rising procedure volumes as structural drivers for devices used in joint replacement, cardiovascular interventions and minimally invasive surgery.

Analyst views on the stock

Analysts continue to emphasize the defensive qualities of Johnson & Johnson shares, citing the company’s diversified revenue base and strong balance sheet.MarketScreener consensus data on Johnson & Johnson Consensus data compiled by MarketScreener show a majority of covering analysts rating the stock as Buy or Hold, with the average 12-month price target implying modest upside from recent trading levels.Morningstar analysis on Johnson & Johnson

Dividend stability is a recurring theme in coverage, as Johnson & Johnson has increased its payout for more than 60 consecutive years and is classified as a dividend aristocrat in the S&P 500.Johnson & Johnson dividend increase announcement Research houses such as UBS and JPMorgan underline that predictable cash flows from pharmaceuticals and medtech underpin the dividend policy, even as the group continues to invest heavily in research and development.UBS equity research on Johnson & Johnson

Key products driving revenue

Johnson & Johnson generates a large portion of its pharmaceutical revenue from immunology, oncology and neuroscience therapies, including Stelara for inflammatory diseases and Darzalex for multiple myeloma.Johnson & Johnson 2025 annual report segment overview In medtech, important lines include joint-replacement systems within the DePuy Synthes portfolio and electrophysiology catheters under the Biosense Webster brand.

Where the stock trades today

Johnson & Johnson shares trade primarily on the New York Stock Exchange under the ticker JNJ, with the latest available quote around 150 US dollars per share as of 2026-06-26, according to exchange data.NYSE quote for JNJ

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.